Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Questionable efficacy of the rVSV-ZEBOV Ebola vaccine

We read with great interest the final report by Ana Maria Henao-Restrepo and colleagues (Feb 4, 2017, p 505)1 on the ring vaccination trial of an rVSV-vectored vaccine for Ebola virus disease (rVSV-ZEBOV). Briefly, among 2119 people who received the vaccine immediately, no cases of Ebola virus disease were identified in a period of 11 days (10–21 days after vaccination). By contrast, 16 cases were identified within the same time frame among 2041 people who did not receive the vaccine immediately.